A detailed history of Tower Research Capital LLC (Trc) transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 12,500 shares of BCRX stock, worth $94,625. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,500
Previous 56,554 77.9%
Holding current value
$94,625
Previous $349,000 72.78%
% of portfolio
0.0%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.41 - $8.69 $282,386 - $382,829
-44,054 Reduced 77.9%
12,500 $95,000
Q2 2024

Aug 13, 2024

BUY
$4.13 - $6.79 $218,613 - $359,415
52,933 Added 1461.83%
56,554 $349,000
Q1 2024

May 15, 2024

SELL
$4.89 - $7.65 $33,247 - $52,012
-6,799 Reduced 65.25%
3,621 $18,000
Q4 2023

Feb 13, 2024

BUY
$4.98 - $6.77 $29,441 - $40,024
5,912 Added 131.14%
10,420 $62,000
Q3 2023

Nov 14, 2023

SELL
$6.71 - $7.92 $127,583 - $150,590
-19,014 Reduced 80.83%
4,508 $31,000
Q2 2023

Aug 14, 2023

BUY
$6.96 - $8.81 $81,592 - $103,279
11,723 Added 99.36%
23,522 $165,000
Q1 2023

May 09, 2023

SELL
$7.94 - $11.84 $35,150 - $52,415
-4,427 Reduced 27.28%
11,799 $98,000
Q4 2022

Feb 10, 2023

SELL
$10.5 - $14.2 $320,113 - $432,915
-30,487 Reduced 65.26%
16,226 $186,000
Q3 2022

Nov 10, 2022

BUY
$10.79 - $14.81 $117,093 - $160,718
10,852 Added 30.26%
46,713 $589,000
Q2 2022

Aug 15, 2022

BUY
$7.89 - $17.88 $155,283 - $351,896
19,681 Added 121.64%
35,861 $380,000
Q1 2022

May 12, 2022

SELL
$11.56 - $19.76 $99,982 - $170,904
-8,649 Reduced 34.83%
16,180 $263,000
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $157,146 - $217,305
-14,056 Reduced 36.15%
24,829 $344,000
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $275,858 - $342,639
19,413 Added 99.7%
38,885 $559,000
Q2 2021

Aug 16, 2021

SELL
$9.5 - $17.24 $395,504 - $717,735
-41,632 Reduced 68.13%
19,472 $308,000
Q1 2021

May 17, 2021

SELL
$7.37 - $13.61 $20,149 - $37,209
-2,734 Reduced 4.28%
61,104 $622,000
Q4 2020

Feb 16, 2021

SELL
$3.37 - $8.61 $1.28 Million - $3.27 Million
-379,797 Reduced 85.61%
63,838 $475,000
Q3 2020

Nov 16, 2020

BUY
$3.43 - $5.53 $1.18 Million - $1.9 Million
343,144 Added 341.47%
443,635 $1.52 Million
Q2 2020

Aug 13, 2020

BUY
$1.9 - $5.61 $190,932 - $563,754
100,491 New
100,491 $479,000
Q2 2019

Aug 13, 2019

SELL
$2.91 - $9.15 $1,027 - $3,229
-353 Closed
0 $0
Q1 2019

May 14, 2019

BUY
$7.38 - $9.72 $2,605 - $3,431
353 New
353 $3,000
Q1 2018

May 15, 2018

SELL
$4.35 - $5.82 $1,322 - $1,769
-304 Closed
0 $0
Q4 2017

Feb 09, 2018

SELL
$4.16 - $5.33 $38,001 - $48,689
-9,135 Reduced 96.78%
304 $1,000
Q3 2017

Nov 14, 2017

BUY
$4.1 - $5.97 $38,699 - $56,350
9,439
9,439 $50,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.